Methods To construct this review article, we performed a systematic review of the literature to
identify relevant studies comparing anti-TNF monotherapy to combination therapy with an …

Background Anti‐tumour necrosis factor‐α (TNF α) antibodies are efficacious in
inflammatory bowel disease (IBD). These drugs carry the theoretical risk of malignancy …

Inflammatory bowel disease (IBD), in particular Crohn's disease refractory to conventional
therapy, fistulizing Crohn's disease and chronic active ulcerative colitis, generally respond …

INTRODUCTION Biologic therapies include:(1) naturally occurring or modified biologic
compounds such as vaccines (live, live attenuated, or killed microorganisms), hormone …

Background Anti‐tumour necrosis factor‐alpha agents (anti‐TNF) are effective therapies for
the treatment of Crohn's disease (CD), but their comparative efficacy is unknown. Aim To …

Background One‐third of patients with Crohn's disease (CD) or ulcerative colitis (UC)
receiving anti‐TNF s do not respond to treatment, and a relevant proportion experience loss …

Six biologic agents are currently approved for the treatment of IBD: four anti-TNF agents
(infliximab, adalimumab, golimumab and certolizumab pegol) and two anti-integrin agents …

Objectives In patients with IBD experiencing an immune-mediated loss of response (LOR) to
antitumour necrosis factor (anti-TNF), algorithms recommend a switch of anti-TNF without …

Vermeire and colleagues have furth-ered our understanding of the effectiveness of
concomitant immunosuppressive therapy in suppressing formation of antibodies to …

Background and aims Concomitant use of immunosuppressants (IS) with scheduled
infliximab (IFX) maintenance therapy for Crohn's disease (CD) or ulcerative colitis (UC) is …